Gene-drug interactions (data source: DGIdb)
Gene Name Entrez ID Drug Name Chembl ID Interaction Types Sources publications
HTR2A 3356 ITI-007 (CHEMBL3545044) CHEMBL3545044 antagonist TdgClinicalTrial, ChemblInteractions
HTR2A 3356 CLOZAPINE CHEMBL42 antagonist TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions, NCI, TEND, DrugBank 14687870, 14751426, 14530903, 15037867, 12973385, 7520908, 8916101, 9926100
HTR2A 3356 TRIFLUOPERAZINE HYDROCHLORIDE CHEMBL1710 antagonist ChemblInteractions
HTR2A 3356 PROMAZINE CHEMBL564 antagonist TdgClinicalTrial, TEND, DrugBank 17139284, 17016423, 10980325, 12106771
HTR2A 3356 AMOXAPINE CHEMBL1113 antagonist DrugBank 8876023
HTR2A 3356 LISURIDE CHEMBL157138 agonist GuideToPharmacologyInteractions, DrugBank 18691132, 9600588
HTR2A 3356 APOMORPHINE CHEMBL53 agonist, antagonist GuideToPharmacologyInteractions, DrugBank 18691132
HTR2A 3356 PROPIOMAZINE CHEMBL1201210 antagonist TdgClinicalTrial, TEND, DrugBank 17139284, 17016423
HTR2A 3356 MINAPRINE CHEMBL278819 antagonist TdgClinicalTrial, TEND, DrugBank 3836113, 1361012, 2975224, 2530096
HTR2A 3356 ARIPIPRAZOLE CHEMBL1112 agonist, antagonist TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions, TEND, DrugBank 14642974, 17265076, 17242925
HTR2A 3356 METHYLENEDIOXYMETHAMPHETAMINE CHEMBL43048 agonist DrugBank 2871581, 7824160
HTR2A 3356 ILOPERIDONE CHEMBL14376 antagonist TdgClinicalTrial, ChemblInteractions, DrugBank, TTD 12861482, 8997630
HTR2A 3356 TEMANOGREL CHEMBL1084617 inverse agonist TdgClinicalTrial, ChemblInteractions, DrugBank
HTR2A 3356 CHEMBL609728 CHEMBL609728 DrugBank
HTR2A 3356 BUTRIPTYLINE CHEMBL2110816 antagonist DrugBank 3816971, 9537821, 6086881
HTR2A 3356 VABICASERIN HYDROCHLORIDE CHEMBL2104991 antagonist ChemblInteractions
HTR2A 3356 CHLORPROMAZINE CHEMBL71 antagonist GuideToPharmacologyInteractions, ChemblInteractions
HTR2A 3356 TRAZODONE HYDROCHLORIDE CHEMBL1200798 antagonist ChemblInteractions
HTR2A 3356 LOXAPINE HYDROCHLORIDE CHEMBL1201060 antagonist ChemblInteractions
HTR2A 3356 PALIPERIDONE PALMITATE CHEMBL1201732 antagonist ChemblInteractions
HTR2A 3356 PIMOZIDE CHEMBL1423 antagonist GuideToPharmacologyInteractions, ChemblInteractions
HTR2A 3356 ZIPRASIDONE HYDROCHLORIDE CHEMBL1712 antagonist ChemblInteractions
HTR2A 3356 ZIPRASIDONE MESYLATE CHEMBL1200997 antagonist ChemblInteractions
HTR2A 3356 ZIPRASIDONE CHEMBL708 antagonist TdgClinicalTrial, GuideToPharmacologyInteractions, TEND
HTR2A 3356 CHEMBL1079460 CHEMBL1079460 inhibitor TTD
HTR2A 3356 NEFAZODONE CHEMBL623 antagonist TdgClinicalTrial, GuideToPharmacologyInteractions, TEND
HTR2A 3356 PIMAVANSERIN TARTRATE CHEMBL2448613 inverse agonist ChemblInteractions
HTR2A 3356 BLONANSERIN CHEMBL178803 antagonist GuideToPharmacologyInteractions, TTD
HTR2A 3356 SARPOGRELATE CHEMBL52939 antagonist GuideToPharmacologyInteractions, TTD
HTR2A 3356 SEROTONIN CHEMBL39 agonist GuideToPharmacologyInteractions
HTR2A 3356 CHEMBL133455 CHEMBL133455 agonist GuideToPharmacologyInteractions
HTR2A 3356 GR-127935 CHEMBL15928 agonist GuideToPharmacologyInteractions
HTR2A 3356 PINDOLOL CHEMBL500 agonist, antagonist GuideToPharmacologyInteractions
HTR2A 3356 QUINPIROLE CHEMBL240773 agonist GuideToPharmacologyInteractions
HTR2A 3356 RU-24969 CHEMBL18785 agonist GuideToPharmacologyInteractions
HTR2A 3356 CHEMBL20963 CHEMBL20963 agonist GuideToPharmacologyInteractions
HTR2A 3356 CYAMEMAZINE CHEMBL2104153 antagonist GuideToPharmacologyInteractions
HTR2A 3356 CHEMBL1356280 CHEMBL1356280 antagonist GuideToPharmacologyInteractions
HTR2A 3356 MESULERGINE CHEMBL12314 antagonist GuideToPharmacologyInteractions
HTR2A 3356 METERGOLINE CHEMBL19215 antagonist GuideToPharmacologyInteractions
HTR2A 3356 MOLINDONE CHEMBL460 antagonist GuideToPharmacologyInteractions
HTR2A 3356 ROXINDOLE CHEMBL431367 antagonist GuideToPharmacologyInteractions
HTR2A 3356 SB-243213 CHEMBL14460 antagonist GuideToPharmacologyInteractions
HTR2A 3356 SPIPERONE CHEMBL267930 antagonist GuideToPharmacologyInteractions
HTR2A 3356 ERGOCALCIFEROL CHEMBL1536 antagonist GuideToPharmacologyInteractions
HTR2A 3356 [3H]KETANSERIN CHEMBL1628637 antagonist GuideToPharmacologyInteractions
HTR2A 3356 VORTIOXETINE CHEMBL2104993 antagonist GuideToPharmacologyInteractions
HTR2A 3356 XANOMELINE CHEMBL21536 antagonist GuideToPharmacologyInteractions
HTR2A 3356 METHYSERGIDE CHEMBL1065 antagonist TdgClinicalTrial, GuideToPharmacologyInteractions, TEND, DrugBank 11704657, 10455282, 11720080, 11061982, 10080233
HTR2A 3356 CABERGOLINE CHEMBL1201087 agonist GuideToPharmacologyInteractions, DrugBank 10641988, 18691132, 18992242, 20426763
HTR2A 3356 ROPINIROLE CHEMBL589 agonist DrugBank 18691132
HTR2A 3356 MIRTAZAPINE CHEMBL654 antagonist TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions, TEND, DrugBank 10446738, 11063897, 10451911, 10446735, 10446734, 11607047
HTR2A 3356 LOXAPINE CHEMBL831 antagonist TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions, DrugBank 12664192
HTR2A 3356 PIPOTIAZINE CHEMBL398880 antagonist DrugBank 8593484, 10821438
HTR2A 3356 FLUSPIRILENE CHEMBL46516 antagonist GuideToPharmacologyInteractions, DrugBank 8935801
HTR2A 3356 NELOTANSERIN CHEMBL598172 inverse agonist TdgClinicalTrial, ChemblInteractions, DrugBank
HTR2A 3356 LY2624803 CHEMBL3545287 DrugBank
HTR2A 3356 CHEMBL513521 CHEMBL513521 DrugBank
HTR2A 3356 LURASIDONE CHEMBL1237021 antagonist TdgClinicalTrial, DrugBank 23545936
HTR2A 3356 LITHIUM CHEMBL2146126 NCI 10758249
HTR2A 3356 FANANSERIN CHEMBL83894 antagonist TTD
HTR2A 3356 ESMIRTAZAPINE MALEATE CHEMBL2107339 antagonist ChemblInteractions
HTR2A 3356 IFERANSERIN CHEMBL2107754 antagonist TdgClinicalTrial, ChemblInteractions
HTR2A 3356 LURASIDONE HYDROCHLORIDE CHEMBL1615372 antagonist ChemblInteractions, TTD
HTR2A 3356 QUETIAPINE FUMARATE CHEMBL1200911 antagonist ChemblInteractions
HTR2A 3356 THIETHYLPERAZINE CHEMBL1378 TdgClinicalTrial, TEND
HTR2A 3356 CYCLOBENZAPRINE HYDROCHLORIDE CHEMBL1200636 antagonist ChemblInteractions
HTR2A 3356 DOXEPIN CHEMBL1628227 TdgClinicalTrial
HTR2A 3356 PROCHLORPERAZINE CHEMBL728 TEND
HTR2A 3356 AMITRIPTYLINE CHEMBL629 TdgClinicalTrial
HTR2A 3356 ASENAPINE (CHEMBL3187365) CHEMBL3187365 antagonist TdgClinicalTrial, GuideToPharmacologyInteractions
HTR2A 3356 CYCLOBENZAPRINE CHEMBL669 TdgClinicalTrial, TEND
HTR2A 3356 ADATANSERIN CHEMBL2111138 antagonist TTD
HTR2A 3356 ARIPIPRAZOLE LAUROXIL CHEMBL2219425 antagonist ChemblInteractions
HTR2A 3356 NEFAZODONE HYDROCHLORIDE CHEMBL1200492 antagonist ChemblInteractions
HTR2A 3356 CHEMBL1188853 CHEMBL1188853 antagonist TTD
HTR2A 3356 LUBAZODONE HYDROCHLORIDE CHEMBL1822892 inhibitor TTD
HTR2A 3356 5-METHOXYTRYPTAMINE CHEMBL8165 agonist GuideToPharmacologyInteractions
HTR2A 3356 8-OH-DPAT CHEMBL56 agonist GuideToPharmacologyInteractions
HTR2A 3356 BROLAMFETAMINE CHEMBL6607 agonist GuideToPharmacologyInteractions
HTR2A 3356 METHYLERGONOVINE CHEMBL1201356 agonist GuideToPharmacologyInteractions
HTR2A 3356 PERGOLIDE CHEMBL531 agonist GuideToPharmacologyInteractions
HTR2A 3356 TRYPTAMINE CHEMBL6640 agonist GuideToPharmacologyInteractions
HTR2A 3356 BROMOCRIPTINE CHEMBL493 agonist GuideToPharmacologyInteractions
HTR2A 3356 CHLOROPHENYLPIPERAZINE CHEMBL478 agonist GuideToPharmacologyInteractions
HTR2A 3356 AGOMELATINE CHEMBL10878 antagonist GuideToPharmacologyInteractions
HTR2A 3356 ACETIC ACID CHEMBL539 antagonist GuideToPharmacologyInteractions
HTR2A 3356 FLUPHENAZINE CHEMBL726 antagonist GuideToPharmacologyInteractions
HTR2A 3356 GLEMANSERIN CHEMBL18972 antagonist GuideToPharmacologyInteractions
HTR2A 3356 PIPAMPERONE CHEMBL440294 antagonist GuideToPharmacologyInteractions
HTR2A 3356 SB-224289 CHEMBL281350 antagonist GuideToPharmacologyInteractions
HTR2A 3356 TRIFLUOPERAZINE CHEMBL422 antagonist GuideToPharmacologyInteractions
HTR2A 3356 VENLAFAXINE CHEMBL637 PharmGKB
HTR2A 3356 CHLORPROTHIXENE CHEMBL908 antagonist TdgClinicalTrial, ChemblInteractions, TEND, DrugBank 2891550, 3774629
HTR2A 3356 THIOTHIXENE HYDROCHLORIDE CHEMBL1200902 antagonist ChemblInteractions
HTR2A 3356 OLANZAPINE CHEMBL715 antagonist PharmGKB, TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions, TEND, DrugBank 17848919, 11752352, 15816787, 16905159, 14530903, 10227113, 17316700, 16038601, 15358979
HTR2A 3356 ERGOTAMINE CHEMBL442 agonist GuideToPharmacologyInteractions, DrugBank 2758221, 8014033, 11752352
HTR2A 3356 TEGASEROD CHEMBL76370 antagonist DrugBank 15466450
HTR2A 3356 YOHIMBINE CHEMBL15245 antagonist DrugBank 8032658, 6136920
HTR2A 3356 ACEPROMAZINE CHEMBL39560 antagonist DrugBank 8593484, 10821438
HTR2A 3356 ZUCLOPENTHIXOL CHEMBL87385 antagonist DrugBank 12957216, 8748043, 19644682
HTR2A 3356 FLIBANSERIN CHEMBL231068 agonist, antagonist TdgClinicalTrial, GuideToPharmacologyInteractions, DrugBank, TTD 12890707, 12177684, 26412054
HTR2A 3356 AMISULPRIDE CHEMBL243712 antagonist DrugBank 15204055
HTR2A 3356 DERAMCICLANE CHEMBL2104698 antagonist DrugBank 10445375
HTR2A 3356 CARPHENAZINE MALEATE CHEMBL2358147 antagonist ChemblInteractions
HTR2A 3356 VOLINANSERIN CHEMBL74355 antagonist TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions
HTR2A 3356 EPLIVANSERIN CHEMBL257704 antagonist ChemblInteractions
HTR2A 3356 ASENAPINE MALEATE CHEMBL3544974 antagonist ChemblInteractions
HTR2A 3356 LOXAPINE SUCCINATE CHEMBL1201155 antagonist ChemblInteractions
HTR2A 3356 PROMAZINE HYDROCHLORIDE CHEMBL1200469 antagonist ChemblInteractions
HTR2A 3356 EPLIVANSERIN FUMARATE CHEMBL2103845 binder TTD
HTR2A 3356 PAROXETINE CHEMBL490 PharmGKB
HTR2A 3356 QUETIAPINE CHEMBL716 agonist, antagonist TdgClinicalTrial, GuideToPharmacologyInteractions, TEND
HTR2A 3356 CYPROHEPTADINE CHEMBL516 TdgClinicalTrial, TEND
HTR2A 3356 CHEMBL430798 CHEMBL430798 antagonist TTD
HTR2A 3356 MESORIDAZINE BESYLATE CHEMBL1201052 antagonist ChemblInteractions
HTR2A 3356 HALOPERIDOL CHEMBL54 antagonist GuideToPharmacologyInteractions, ChemblInteractions
HTR2A 3356 CHEMBL504548 CHEMBL504548 antagonist TTD
HTR2A 3356 NEMIFITIDE CHEMBL2107761 TdgClinicalTrial
HTR2A 3356 THIORIDAZINE HYDROCHLORIDE CHEMBL1200916 antagonist ChemblInteractions
HTR2A 3356 TRIMIPRAMINE MALEATE CHEMBL1200948 antagonist ChemblInteractions
HTR2A 3356 RELENOPRIDE CHEMBL3544975 agonist GuideToPharmacologyInteractions
HTR2A 3356 BRL-15,572 CHEMBL534232 agonist GuideToPharmacologyInteractions
HTR2A 3356 EPOPROSTENOL CHEMBL1139 agonist GuideToPharmacologyInteractions
HTR2A 3356 LORCASERIN CHEMBL360328 agonist GuideToPharmacologyInteractions
HTR2A 3356 LYSERGIDE CHEMBL263881 agonist GuideToPharmacologyInteractions
HTR2A 3356 CHEMBL3186179 CHEMBL3186179 agonist GuideToPharmacologyInteractions
HTR2A 3356 CHEMBL506999 CHEMBL506999 agonist GuideToPharmacologyInteractions
HTR2A 3356 CHEMBL309760 CHEMBL309760 agonist GuideToPharmacologyInteractions
HTR2A 3356 CHEMBL1255588 CHEMBL1255588 antagonist GuideToPharmacologyInteractions
HTR2A 3356 DULOXETINE CHEMBL1175 antagonist GuideToPharmacologyInteractions
HTR2A 3356 ACETAMIDE CHEMBL16081 antagonist GuideToPharmacologyInteractions
HTR2A 3356 ACETONE CHEMBL14253 antagonist GuideToPharmacologyInteractions
HTR2A 3356 CHEMBL52422 CHEMBL52422 antagonist GuideToPharmacologyInteractions
HTR2A 3356 METITEPINE CHEMBL93240 antagonist GuideToPharmacologyInteractions
HTR2A 3356 RS-102,221 CHEMBL88402 antagonist GuideToPharmacologyInteractions
HTR2A 3356 CHEMBL473186 CHEMBL473186 antagonist GuideToPharmacologyInteractions
HTR2A 3356 CHEMBL14276 CHEMBL14276 antagonist GuideToPharmacologyInteractions
HTR2A 3356 SB-242084 CHEMBL14563 antagonist GuideToPharmacologyInteractions
HTR2A 3356 SPIRAMIDE CHEMBL79834 antagonist GuideToPharmacologyInteractions
HTR2A 3356 Trelanserin CHEMBL3183740 antagonist TdgClinicalTrial, ChemblInteractions
HTR2A 3356 CHLORPROMAZINE HYDROCHLORIDE CHEMBL1713 antagonist ChemblInteractions
HTR2A 3356 THIOTHIXENE CHEMBL1201 antagonist GuideToPharmacologyInteractions, ChemblInteractions, DrugBank 8593484, 10821438
HTR2A 3356 CISAPRIDE CHEMBL1729 agonist DrugBank 1969947, 11131599, 8423526
HTR2A 3356 RISPERIDONE CHEMBL85 antagonist PharmGKB, TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions, TEND, DrugBank, TTD 15907153, 17316700, 15992090, 11132243
HTR2A 3356 FLUPENTIXOL CHEMBL54661 antagonist DrugBank 17111172
HTR2A 3356 MESORIDAZINE CHEMBL1088 antagonist TdgClinicalTrial, GuideToPharmacologyInteractions, TEND, DrugBank 10991983, 11561066, 15357957
HTR2A 3356 N-DESMETHYLCLOZAPINE CHEMBL845 TdgClinicalTrial
HTR2A 3356 PALIPERIDONE CHEMBL1621 antagonist TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions, TEND, DrugBank 12211096, 11132243, 7542676, 7531353, 7524043, 7520908
HTR2A 3356 LEVOMEPROMAZINE CHEMBL1764 antagonist DrugBank 15701205
HTR2A 3356 CHEMBL126506 CHEMBL126506 agonist DrugBank 17209801, 17139284, 17016423, 9666084, 10987842
HTR2A 3356 N,N-DIMETHYLTRYPTAMINE CHEMBL12420 DrugBank 19278957, 2540505
HTR2A 3356 THIOPROPERAZINE CHEMBL609109 antagonist DrugBank 8593484, 10821438
HTR2A 3356 DROPERIDOL CHEMBL1108 antagonist ChemblInteractions
HTR2A 3356 MOLINDONE HYDROCHLORIDE CHEMBL1200419 antagonist ChemblInteractions
HTR2A 3356 OLANZAPINE PAMOATE CHEMBL1201741 antagonist ChemblInteractions
HTR2A 3356 HALOPERIDOL DECANOATE CHEMBL1200986 antagonist ChemblInteractions
HTR2A 3356 HALOPERIDOL LACTATE CHEMBL2096643 antagonist ChemblInteractions
HTR2A 3356 THIORIDAZINE CHEMBL479 antagonist TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions, TEND
HTR2A 3356 BIFEPRUNOX CHEMBL218166 TdgClinicalTrial
HTR2A 3356 TRAZODONE CHEMBL621 antagonist TdgClinicalTrial, GuideToPharmacologyInteractions, TEND
HTR2A 3356 ABAPERIDONE (CHEMBL151475) CHEMBL151475 antagonist TTD
HTR2A 3356 CHEMBL2078915 CHEMBL2078915 antagonist TTD
HTR2A 3356 SB-773812 CHEMBL3545102 antagonist ChemblInteractions
HTR2A 3356 OCAPERIDONE CHEMBL2104619 antagonist TTD
HTR2A 3356 FLUOXETINE CHEMBL41 TdgClinicalTrial
HTR2A 3356 PRUVANSERIN CHEMBL1215661 antagonist ChemblInteractions
HTR2A 3356 TERGURIDE CHEMBL73151 agonist TdgClinicalTrial, GuideToPharmacologyInteractions
HTR2A 3356 RENZAPRIDE CHEMBL159825 TdgClinicalTrial
HTR2A 3356 TEDATIOXETINE CHEMBL2104986 antagonist ChemblInteractions
HTR2A 3356 CHEMBL1600780 CHEMBL1600780 agonist GuideToPharmacologyInteractions
HTR2A 3356 DONITRIPTAN CHEMBL1742428 agonist GuideToPharmacologyInteractions
HTR2A 3356 CHEMBL134519 CHEMBL134519 agonist GuideToPharmacologyInteractions
HTR2A 3356 MK-212 CHEMBL269521 agonist GuideToPharmacologyInteractions
HTR2A 3356 QUIPAZINE CHEMBL18772 agonist GuideToPharmacologyInteractions
HTR2A 3356 CHEMBL76781 CHEMBL76781 agonist GuideToPharmacologyInteractions
HTR2A 3356 Capeserod CHEMBL2027925 agonist GuideToPharmacologyInteractions
HTR2A 3356 AMESERGIDE CHEMBL160293 antagonist GuideToPharmacologyInteractions
HTR2A 3356 BUFOTENINE CHEMBL416526 antagonist GuideToPharmacologyInteractions
HTR2A 3356 PERPHENAZINE CHEMBL567 antagonist GuideToPharmacologyInteractions
HTR2A 3356 RITANSERIN CHEMBL267777 antagonist GuideToPharmacologyInteractions
HTR2A 3356 CHEMBL65280 CHEMBL65280 antagonist GuideToPharmacologyInteractions
HTR2A 3356 CHEMBL297784 CHEMBL297784 antagonist GuideToPharmacologyInteractions
HTR2A 3356 CHEMBL316069 CHEMBL316069 antagonist GuideToPharmacologyInteractions
HTR2A 3356 SERGOLEXOLE CHEMBL2110594 antagonist GuideToPharmacologyInteractions
HTR2A 3356 ZOTEPINE CHEMBL285802 antagonist GuideToPharmacologyInteractions
HTR2A 3356 REMOXIPRIDE CHEMBL22242 DrugBank 9015795
HTR2A 3356 ONDANSETRON CHEMBL46 NCI 9767524
HTR2A 3356 ANIRACETAM CHEMBL36994 DrugBank 11412837
HTR2A 3356 SERTINDOLE CHEMBL12713 antagonist TdgClinicalTrial, GuideToPharmacologyInteractions, TEND, DrugBank 16925508, 7530204, 11594443
HTR2A 3356 ESMIRTAZAPINE CHEMBL1366933 inverse agonist TdgClinicalTrial, DrugBank 26047892
HTR2A 3356 MIANSERIN CHEMBL6437 antagonist TdgClinicalTrial, GuideToPharmacologyInteractions, TEND, DrugBank 11004734
HTR2A 3356 PIMAVANSERIN CHEMBL2111101 antagonist, inverse agonist TdgClinicalTrial, GuideToPharmacologyInteractions, DrugBank, TTD 24016069
HTR2A 3356 BREXPIPRAZOLE CHEMBL2105760 antagonist TdgClinicalTrial, ChemblInteractions, DrugBank 24947465
HTR2A 3356 KETANSERIN CHEMBL51 antagonist GuideToPharmacologyInteractions, NCI 9767524
HTR2A 3356 CARIPRAZINE CHEMBL2028019 antagonist DrugBank 26510944
HTR2A 3356 CINITAPRIDE CHEMBL2104523 antagonist DrugBank 9562338, 9211565
HTR2A 3356 AMPEROZIDE CHEMBL1079935 antagonist DrugBank 2154737

Variant-drug associations (data source: PharmGKB)
Gene Name Variant Alleles Chemical Phenotype Category Significance Notes Sentence Publications Annotation ID
HTR2A rs6313 AA + AG risperidone efficacy yes Although there was no significant difference between responders and non-responders in terms of overall PANSS score, a significantly increased improvement in negative symptoms was noted across the genotypes GG<AG<AA. Genotypes AA + AG are associated with increased response to risperidone in people with Schizophrenia as compared to genotype GG. 32462699 1451151829
HTR2A rs6313 AA + AG olanzapine efficacy yes Although there was no significant difference between responders and non-responders in terms of overall PANSS score, a significantly better response in the Emsley's positive dimension was observed in carriers of the A allele. Please note that alleles have been complemented to the positive strand. Genotypes AA + AG are associated with increased response to olanzapine in people with Schizophrenia as compared to genotype GG. 32462699 1451151860
HTR2A rs6313 AG + GG olanzapine efficacy yes Although there was no significant difference between responders and non-responders in terms of overall PANSS score, a significantly better response in the Emsley's anxiety factor was observed in carriers of the G allele. Please note that alleles have been complemented to the positive strand. Genotypes AG + GG are associated with increased response to olanzapine in people with Schizophrenia as compared to genotype AA. 32462699 1451151848
HTR2A rs6311 CT + TT risperidone efficacy yes as measured by decrease in ATEC score. Alleles complemented to plus chromosomal strand. Genotypes CT + TT are associated with increased response to risperidone in children with Autistic Disorder as compared to genotype CC. 19997080 655387233
HTR2A rs6313 A morphine efficacy no No significant difference in improvement in pain scores between genotype groups. Allele A is not associated with response to morphine and nortriptyline in people with Pain as compared to allele G. 31738228 1451133740
HTR2A rs6311 CC antidepressants efficacy no Genotype CC is not associated with response to antidepressants in people with Depressive Disorder, Major as compared to genotypes CT + TT. 23733030 982028673
HTR2A rs7997012 GG antidepressants efficacy no Genotype GG is not associated with response to antidepressants in people with Depressive Disorder, Major as compared to genotypes AA + AG. 23733030 982028703
HTR2A rs6313 AA + AG antidepressants efficacy no Genotypes AA + AG are not associated with response to antidepressants in people with Depressive Disorder, Major as compared to genotype GG. 23733030 982028694
HTR2A rs6311 T escitalopram efficacy no Allele T is not associated with response to escitalopram in people with Depression as compared to allele C. 31721892 1451148566
HTR2A rs6313 A escitalopram efficacy no Allele A is not associated with response to escitalopram in people with Depression as compared to allele G. 31721892 1451148571
HTR2A rs7997012 A escitalopram efficacy no Allele A is not associated with response to escitalopram in people with Depression as compared to allele G. 31721892 1451148576
HTR2A rs7997012 A escitalopram efficacy no Participants were enrolled in a 6 week, forced titration, open label examination. Doses started at 2.5 mg/day up to a possible dose of 20 mg/ day. The study compared AA to AG to GG genotypes and found no significant association. Allele A is not associated with increased response to escitalopram in people with Autistic Disorder as compared to allele G. 26262902 1448105573
HTR2A rs6311 C citalopram efficacy no This SNP was also not found to be associated with Major Depressive Disorder. Allele C is not associated with response to citalopram, fluoxetine or paroxetine in people with Depressive Disorder, Major as compared to allele T. 19590397 981750795
HTR2A rs7997012 A citalopram efficacy no This SNP was also not found to be associated with Major Depressive Disorder. Allele A is not associated with response to citalopram, fluoxetine or paroxetine in people with Depressive Disorder, Major as compared to allele G. 19590397 981750801
HTR2A rs6313 A citalopram efficacy no This SNP was also not found to be associated with Major Depressive Disorder. Allele A is not associated with response to citalopram, fluoxetine or paroxetine in people with Depressive Disorder, Major as compared to allele G. 19590397 981750786
HTR2A rs6311 C Selective serotonin reuptake inhibitors efficacy no An interaction effect was reported with rs7997012 and gender, such that male patients having AG at rs7997012 and TT at rs6311 had somewhat better improvement in MADRS scores after SSRI (or ECT +/- psychotropic drugs) treatment. Allele C is not associated with response to Selective serotonin reuptake inhibitors in people with Depressive Disorder, Major as compared to allele T. 21741447 981479921
HTR2A rs6314 AG + GG antidepressants efficacy yes 19% tricyclics;17% mirtazapine;14% SSRI; 13% electroconvulsive therapy;13% repetitive transcranial magnetic stimulation; 24% combinations. The improvement was in HAMD-17 score. Genotypes AG + GG are associated with increased response to antidepressants in people with Depressive Disorder, Major as compared to genotype AA. 11311507 981477511
HTR2A rs7997012 A Selective serotonin reuptake inhibitors efficacy no An interaction effect was reported with rs6311 and gender, such that male patients having AG at rs7997012 and TT at rs6311 had somewhat better improvement in MADRS scores after SSRI (or ECT +/- psychotropic drugs) treatment. Allele A is not associated with response to Selective serotonin reuptake inhibitors in people with Depressive Disorder, Major as compared to allele G. 21741447 981479928
HTR2A rs7997012 G morphine efficacy no No significant difference in improvement in pain scores between genotype groups. Allele G is not associated with response to morphine and nortriptyline in people with Pain as compared to allele A. 31738228 1451133746
HTR2A rs6313 G olanzapine efficacy no no p-value reported Allele G is not associated with response to olanzapine in people with Schizophrenia as compared to allele A. 19000940 1183689306
HTR2A rs6311 CC fluvoxamine efficacy yes The association was only found for fluvoxamine treatment not treatment with paroxetine. Genotype CC is associated with increased response to fluvoxamine in people with Depressive Disorder, Major as compared to genotypes CT + TT. 16874005 1183959993
HTR2A rs6311 C fluvoxamine efficacy no No association was found comparing responder vs non-responder. Allele C is not associated with response to fluvoxamine or paroxetine in people with Depressive Disorder, Major as compared to allele T. 16874005 1183960004
HTR2A rs6313 G fluoxetine efficacy no Responders were defined as patients with at least 50% decrease in HAM-D total score after 4-week fluoxetine treatment. Allele G is not associated with increased response to fluoxetine in people with Depressive Disorder, Major as compared to allele A. 16302021 1184511379
HTR2A rs6313 G fluvoxamine efficacy no No association for the overall score was found. In the Italian sample, G allele carriers showed a slower score reduction compared with A allele carriers in Somatic anxiety (MANCOVA: F=3.0, df=3,236, P=0.029) Allele G is associated with response to fluvoxamine or paroxetine in people with Depressive Disorder, Major as compared to allele A. 19361869 1184467092
HTR2A rs6311 C antidepressants efficacy no Meta-analysis with 11 studies. No significant correlation between this SNP and response rate to antidepressants was found, in any genetic model (e.g. allele, dominant, recessive). Please note that alleles have been complemented to the plus chromosomal strand. Allele C is not associated with response to antidepressants in people with Depressive Disorder, Major as compared to allele T. 25108775 1445296437
HTR2A rs6313 GG antidepressants efficacy yes Meta-analysis with 11 studies. Please note that alleles have been complemented to the plus chromosomal strand. Genotype GG is associated with increased response to antidepressants in people with Depressive Disorder, Major as compared to genotypes AA + AG. 25108775 1445296421
HTR2A rs7997012 AG + GG antidepressants efficacy yes Meta-analysis with 11 studies. Genotypes AG + GG is associated with increased response to antidepressants in people with Depressive Disorder, Major as compared to genotype AA. 25108775 1445296428
HTR2A rs6314 GG olanzapine efficacy yes The associations were evaluated in conjunction with rs1076560 in the DRD2 gene. rs1076560 GT/rs6314 CC diplotype was associated with better responses to antipsychotics than the rs1076560 GG/rs6314 CT diplotype Genotype GG is associated with increased response to olanzapine in people with Schizophrenia as compared to genotypes AA + AG. 25563748 1447813766
HTR2A rs2274639 C venlafaxine efficacy no Response assessed as remission, defined as MADRS score =<10 at the end of treatment. Allele C is not associated with response to venlafaxine in people with Depressive Disorder, Major as compared to allele G. 28068779 1448601851
HTR2A rs9567746 A venlafaxine efficacy no Response assessed as remission, defined as MADRS score =<10 at the end of treatment. Allele A is not associated with response to venlafaxine in people with Depressive Disorder, Major as compared to allele G. 28068779 1448601868
HTR2A rs6311 C venlafaxine efficacy no Response assessed as remission, defined as MADRS score =<10 at the end of treatment. Allele C is not associated with response to venlafaxine in people with Depressive Disorder, Major as compared to allele T. 28068779 1448601857
HTR2A rs6311 C opioids dosage no Variant had no significant association with opioid dose in the development sample. Allele C is not associated with dose of opioids in people with Pain as compared to allele T. 21398039 1449714971
HTR2A rs6313 A risperidone efficacy no Please note that alleles have been complemented to the positive strand. Allele A is not associated with response to risperidone in people with Schizophrenia as compared to allele G. 28696411 1450928304
HTR2A rs6311 C risperidone efficacy no Allele C is not associated with response to risperidone in people with Schizophrenia as compared to allele T. 28696411 1450928296
HTR2A rs2770296 CC bupropion efficacy yes Please note that alleles have been complemented to the positive strand. Patients with the CC genotype show a greater reduction in HAMD17 scores as compared to patients with the CT or TT genotypes. Genotype CC is associated with increased response to bupropion in people with Depressive Disorder, Major as compared to genotypes CT + TT. 22947179 1450814583
HTR2A rs6312 C opioids dosage no Variant had no significant association with opioid dose in either the development sample or the validation sample. Please note that alleles have been complemented to the positive strand. Allele C is not associated with dose of opioids in people with Pain as compared to allele T. 21398039 1449714964
HTR2A rs6311 CT + TT ustekinumab efficacy yes as measured by PASI75 at 4 months and adjusted for weight and FDR. Genotypes CT + TT is associated with decreased response to ustekinumab in people with Psoriasis as compared to genotype CC. 27977334 1448594411
HTR2A rs6311 TT buprenorphine efficacy no Response defined by changes in the rate of dropout from treatment between genotypes. Subsequent pairwise analysis resulted in a nominally significant association for the TT genotype compared to the CT genotype in the methadone group and the total cohort, but not in the buprenorphine group. Genotype TT is not associated with response to buprenorphine or methadone in people with Opioid-Related Disorders as compared to genotypes CC + CT. 29333880 1449271273
HTR2A rs6313 G fluvoxamine efficacy no valuated by both total HAM-D and specific symptoms Allele G is not associated with response to fluvoxamine or paroxetine in people with Depressive Disorder, Major as compared to allele A. 19361869 1184467070
HTR2A rs6313 G fluvoxamine efficacy no No association for the overall score was found. In the Japanese sample, A allele carriers showed slower reductions than G allele carriers for Delusion (MANCOVA: F=3.7, df=3,125, P=0.012) and Activity scores (MANCOVA: F=3.3, df=3,153, P=0.021) Allele G is associated with response to fluvoxamine or paroxetine in people with Depressive Disorder, Major as compared to allele A. 19361869 1184467075
HTR2A rs6313 AA propofol dosage yes Patients undergoing thyroid resection surgery. 46/146 of patients with the AA genotype had higher effect-site concentration (Cep) values for propofol (1.85±0.96 µg/ml) versus the100/146 patients with the GA+GG genotypes (1.53±0.76µg/ml). The AA genotype was also associated with longer onset times of propofol induction (3.12±2.68min) versus the GA+GG genotypes (2.19±1.53min). The G allele was also associated with less propofol and less time for propofol to induce anesthesia. Please note: the authors examined 58 SNPs but did not do multiple testing corrections. Genotype AA is associated with decreased dose of propofol as compared to genotypes AG + GG. 28611364 1448639482